Published in Diabetes on September 01, 2004
Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol (2009) 3.43
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther (2006) 2.71
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol (2012) 2.59
Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology (2008) 2.04
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol (2009) 1.77
GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol (2011) 1.62
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest (2014) 1.61
Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia. J Cereb Blood Flow Metab (2011) 1.40
Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab (2009) 1.38
Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care (2009) 1.34
Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest (2011) 1.27
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology (2008) 1.26
Synthesis of heterobifunctional protein fusions using copper-free click chemistry and the aldehyde tag. Angew Chem Int Ed Engl (2012) 1.25
Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells. Adv Drug Deliv Rev (2012) 1.25
Oral delivery of bioencapsulated exendin-4 expressed in chloroplasts lowers blood glucose level in mice and stimulates insulin secretion in beta-TC6 cells. Plant Biotechnol J (2012) 1.21
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. Rev Diabet Stud (2008) 1.19
Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol (2010) 1.17
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol (2013) 1.16
A highly parallel method for synthesizing DNA repeats enables the discovery of 'smart' protein polymers. Nat Mater (2011) 1.14
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord (2010) 1.14
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res (2011) 1.12
Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes (2009) 1.10
Minireview: finding the sweet spot: peripheral versus central glucagon-like peptide 1 action in feeding and glucose homeostasis. Endocrinology (2009) 1.03
Coming full circle in diabetes mellitus: from complications to initiation. Nat Rev Endocrinol (2013) 1.01
Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology (2010) 1.00
Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J Pharmacol Exp Ther (2010) 0.96
A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection. J Control Release (2013) 0.93
Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. PLoS One (2010) 0.93
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther (2011) 0.93
Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control. Proc Natl Acad Sci U S A (2013) 0.92
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med (2013) 0.91
Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience. Diabetes Metab Syndr Obes (2013) 0.89
Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus. J Diabetes Investig (2015) 0.87
GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Br J Pharmacol (2012) 0.87
Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia. Front Endocrinol (Lausanne) (2014) 0.87
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide. World J Diabetes (2015) 0.86
Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes (2008) 0.86
CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol Behav (2008) 0.86
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis. Drugs (2017) 0.86
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins. Rev Diabet Stud (2005) 0.86
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Open Med Chem J (2011) 0.84
Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats. Appetite (2015) 0.84
Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy. Chem Soc Rev (2016) 0.84
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol (2015) 0.84
Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther (2016) 0.82
Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells. Mol Ther (2016) 0.82
Red carpeting the newer antidiabetics. J Pharmacol Pharmacother (2012) 0.81
Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action. PLoS One (2014) 0.81
Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice. J Diabetes Res (2015) 0.81
Understanding mechanism of in vitro maturation, fertilization and culture of sheep embryoes through in silico analysis. Bioinformation (2012) 0.80
Physiological roles of dietary glutamate signaling via gut-brain axis due to efficient digestion and absorption. J Gastroenterol (2013) 0.80
Hetero-bivalent GLP-1/glibenclamide for targeting pancreatic β-cells. Chembiochem (2013) 0.79
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors. World J Diabetes (2014) 0.79
Co-opting biology to deliver drugs. Biotechnol Bioeng (2014) 0.79
A platform for efficient, thiol-stable conjugation to albumin's native single accessible cysteine. Org Biomol Chem (2015) 0.78
A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide. Diabetes Metab Syndr Obes (2015) 0.78
Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment. Bioconjug Chem (2015) 0.78
Homogeneous bispecifics by disulfide bridging. Bioconjug Chem (2014) 0.78
Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes. BMB Rep (2013) 0.78
Site-specific fatty acid-conjugation to prolong protein half-life in vivo. J Control Release (2013) 0.77
Pharmacokinetics of recombinant bifunctional fusion proteins. Expert Opin Drug Metab Toxicol (2012) 0.77
Diabetes and cardiovascular disease: focus on glucagon-like peptide-1 based therapies. Ther Adv Drug Saf (2012) 0.76
Once-weekly albiglutide in the management of type 2 diabetes: patient considerations. Patient Prefer Adherence (2014) 0.76
Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret. J Transl Med (2014) 0.75
Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. J Diabetes Complications (2015) 0.75
Incretin concepts. Diabetes Care (2010) 0.75
Functional screening system for yeast-secreted peptides acting on G-protein coupled receptors. AMB Express (2015) 0.75
Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women. J Diabetes Res (2016) 0.75
Effects of the GLP-1 Agonist Exendin-4 on Intravenous Ethanol Self-Administration in Mice. Alcohol Clin Exp Res (2016) 0.75
Controlled release of biologics for the treatment of type 2 diabetes. J Control Release (2015) 0.75
A brush-polymer conjugate of exendin-4 reduces blood glucose for up to five days and eliminates poly(ethylene glycol) antigenicity. Nat Biomed Eng (2016) 0.75
Biology of incretins: GLP-1 and GIP. Gastroenterology (2007) 10.45
Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med (2009) 8.15
FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. N Engl J Med (2015) 6.48
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation (2008) 4.22
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med (2003) 3.57
Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol (2009) 3.43
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med (2011) 3.31
GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab (2006) 3.28
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem (2002) 3.08
Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab (2013) 2.60
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest (2002) 2.54
GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology (2012) 2.48
DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care (2010) 2.45
Cardiovascular biology of the incretin system. Endocr Rev (2012) 2.42
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology (2010) 2.33
GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med (2013) 2.31
International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25
Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma. Clin Cancer Res (2008) 2.23
Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe (2013) 2.14
Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab (2007) 2.12
Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest (2004) 2.11
Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol (2008) 2.03
Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest (2005) 2.01
Discovery of biomarkers of endometrial receptivity through a minimally invasive approach: a validation study with implications for assisted reproduction. Fertil Steril (2013) 1.98
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest (2006) 1.96
Crystal structures of truncated alphaA and alphaB crystallins reveal structural mechanisms of polydispersity important for eye lens function. Protein Sci (2010) 1.95
Modulation of taste sensitivity by GLP-1 signaling. J Neurochem (2008) 1.89
Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. Diabetes (2006) 1.83
A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res (2007) 1.80
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol (2009) 1.79
Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci (2003) 1.74
Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology (2009) 1.74
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med (2013) 1.72
Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology (2005) 1.71
Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes (2010) 1.71
Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency. Diabetes (2013) 1.64
Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol (2010) 1.64
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes (2009) 1.62
The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab (2008) 1.58
Clinical decisions. Management of type 2 diabetes. N Engl J Med (2008) 1.58
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice. Regul Pept (2005) 1.57
Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer (2009) 1.57
Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes (2003) 1.55
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology (2004) 1.53
Growth differentiation factor 5 regulates cardiac repair after myocardial infarction. J Am Coll Cardiol (2010) 1.51
The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology (2007) 1.45
Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology (2010) 1.42
beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes (2005) 1.41
A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation (2012) 1.39
Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes (2007) 1.39
Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT). Mol Biosyst (2008) 1.37
Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes (2012) 1.29
Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology (2003) 1.28
Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest (2011) 1.27
Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes (2003) 1.26
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology (2008) 1.26
An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis. Gastroenterology (2008) 1.26
Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology (2011) 1.25
Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes (2007) 1.24
GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Mol Cell Endocrinol (2007) 1.24
Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes (2008) 1.24
Glucagon-like Peptide-2. Annu Rev Nutr (2006) 1.22
Role of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensing. Diabetes (2008) 1.22
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens (2009) 1.21
Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology (2007) 1.20
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest (2011) 1.20
Cytokines tumor necrosis factor-α and interferon-γ induce pancreatic β-cell apoptosis through STAT1-mediated Bim protein activation. J Biol Chem (2011) 1.20
ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology (2009) 1.17
Collagen I but not Matrigel matrices provide an MMP-dependent barrier to ovarian cancer cell penetration. BMC Cancer (2008) 1.17
Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev (2012) 1.17
Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int (2011) 1.17
Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am J Pathol (2011) 1.17
Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor. Diabetes (2012) 1.17
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat Rev Endocrinol (2013) 1.16
GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am J Physiol Regul Integr Comp Physiol (2014) 1.16
Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab (2008) 1.15
Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology (2009) 1.15
Modulation of taste sensitivity by GLP-1 signaling in taste buds. Ann N Y Acad Sci (2009) 1.12
The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology (2008) 1.10
Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. Diabetes (2009) 1.10
Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes (2011) 1.10
The role of central glucagon-like peptide-1 in mediating the effects of visceral illness: differential effects in rats and mice. Endocrinology (2004) 1.09
Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med (2006) 1.07
Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev (2014) 1.06
Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology (2005) 1.06
GammaD-crystallin associated protein aggregation and lens fiber cell denucleation. Invest Ophthalmol Vis Sci (2007) 1.06
Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells. Diabetes (2006) 1.05
ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. Gastroenterology (2010) 1.04
Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes (2004) 1.04
Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connect Tissue Res (2002) 1.03
A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice. Diabetes (2007) 1.02
Ciliary neurotrophic factor recruitment of glucagon-like peptide-1 mediates neurogenesis, allowing immortalization of adult murine hypothalamic neurons. FASEB J (2009) 1.01
Subunit exchange, conformational stability, and chaperone-like function of the small heat shock protein 16.5 from Methanococcus jannaschii. J Biol Chem (2002) 1.01